7.33
-0.16 (-2.14%)
| Previous Close | 7.49 |
| Open | 7.41 |
| Volume | 1,270,322 |
| Avg. Volume (3M) | 1,961,303 |
| Market Cap | 1,089,106,048 |
| Price / Sales | 6.03 |
| Price / Book | 5.37 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 |
| Profit Margin | -89.12% |
| Operating Margin (TTM) | -71.30% |
| Diluted EPS (TTM) | -1.08 |
| Quarterly Revenue Growth (YOY) | 3.70% |
| Total Debt/Equity (MRQ) | 109.97% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | -95.21 M |
| Levered Free Cash Flow (TTM) | -24.48 M |
| Return on Assets (TTM) | -16.17% |
| Return on Equity (TTM) | -62.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Adaptive Biotechnologies Corpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.39% |
| % Held by Institutions | 94.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aristotle Atlantic Partners, Llc | 31 Dec 2024 | 2,886,702 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Scotiabank, 63.71%) | Buy |
| Median | 11.00 (50.07%) | |
| Low | 9.00 (Goldman Sachs, 22.78%) | Buy |
| Average | 10.67 (45.57%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 21 Mar 2025 | 9.00 (22.78%) | Buy | 8.40 |
| 28 Jan 2025 | 7.50 (2.32%) | Hold | 7.85 | |
| Piper Sandler | 20 Feb 2025 | 11.00 (50.07%) | Buy | 8.33 |
| Scotiabank | 13 Feb 2025 | 12.00 (63.71%) | Buy | 8.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Apr 2025 | Announcement | Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 |
| 08 Apr 2025 | Announcement | Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma |
| 11 Mar 2025 | Announcement | Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma |
| 11 Feb 2025 | Announcement | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results |
| 05 Feb 2025 | Announcement | Adaptive Biotechnologies to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |